

CURRICULUM VITAE

KENNETH S. HERSHON, M.D.

January 2021

North Shore Diabetes & Endocrine Associates
3003 New Hyde Park Road
Suite 201
New Hyde Park, New York 11042
(516) 327-0850

1981 - Present Partner at North Shore Diabetes & Endocrine Associates
1990 - Present Director of Research at North Shore Diabetes & Endocrine Associates

EDUCATION:

Undergraduate: Brown University, B.S., Chemistry, 1970

Graduate: University of California, Berkeley, M.S.
Chemistry, 1972

Medical School: Albert Einstein College of Medicine, M.D., 1976

POSTGRADUATE TRAINING:

Internship: Mount Sinai Hospital, New York, New York
1976-1977

Residency: Mount Sinai Hospital, New York, New York
Internal Medicine, July 1977 - June 1979

Fellowship: University of Washington, Seattle, Washington
Endocrinology and Metabolism, July 1979 - June 1981

HONORS:

Magna Cum Laude Brown University

Sigma Xi Honor Society Brown University

Alpha Omega Alpha Albert Einstein

BOARD CERTIFICATIONS:

Internal Medicine: 09/12/79

Endocrinology & Metabolism: 11/10/81

AFFILIATIONS:

Long Island Jewish Medical Center, New Hyde Park, NY

North Shore University Hospital, Manhasset, NY

LICENSURE:

September 1977 New York State #132064

ACADEMIC APPOINTMENTS:

Assistant Clinical Professor of Medicine at Hofstra University

2011 to present

Assistant Clinical Professor of Medicine at Albert Einstein College of Medicine –

2000 to 2011

**PROFESSIONAL ORGANIZATION
AND SOCIETIES:**

American Association of Clinical Endocrinologist: Lower New York State Board member
2011 to present

American Association of Clinical Endocrinologist: Acting Lower New York State Chapter
President 2017-4/2018

American Association of Clinical Endocrinologists: Chairman, Lower New York State Chapter
1990-2011

American Association of Clinical Endocrinologists: Board of Directors (National) –
2002-2005

American College of Physicians: Member

American Medical Association: Member

American Diabetes Association: Member

Fellow American College of Endocrinology

Fellow Society of Clinical Densitometry

Fellow of the American College of Physicians – American Society of Internal Medicine

American Association of Clinical Endocrinologists: Former Chairman of the Clinical Research
Committee

CONSULTANT:

Advanced Tissue Science:

Amgen

Aventis

Bristol-Myers Squibb:

Coach Core Curriculum

Eli Lilly

Merck & Co. Inc.:

Monarch

National Diabetes Education Initiative

Diabetic Foot Ulcer Consultant
Consultant

Diabetes and Osteoporosis Consultant

Diabetes Education Consultant

Diabetes Consultant

Diabetes and Growth Hormone Consultant

Diabetes Education and Lipid Consultant

Vascular Biology Consultant

Consultant

Novartis	Diabetes Consultant
Otsuka	Vascular Biology Consultant
Parke-Davis	Regional Consultant Vascular Biology
Pfizer	Diabetic Lipid Consultant
Proctor & Gamble	Osteoporosis Consultant
SmithKline Beecham	Rosiglitazone Consultant
Takeda	Diabetes Consultant
Vascular Biology Workshop	Consultant
Warner Lambert:	Diabetes Consultant
Wyeth-Ayerst	Vascular Biology Consultant

PUBLICATIONS:

Hershon, K. S., Odugbesan, O., & Hirsch, B. R. (2019). Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease. *Clinical Diabetes Online*, 1-10.
doi:<https://doi.org/10.2337/cd18-0040>

Hershon, K. S. (2016). Options for empagliflozin in combination therapy in type 2 diabetes mellitus. *International Journal of General Medicine*, 2016:9, 155-172.
<http://dx.doi.org/10.2147/IJGM.S100288>

Hershon, Kenneth. "Mechanistic Effects of the Renin-Angiotensin-Aldosterone System (RAAS) Blockade in the Prevention of Diabetes." *Endocrine Practice*. 17.May/June (2011): 430-440. Print.

Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team Barzilay J, Braithwaite S, Cheatham WW, Crandell J, Dandona P, Desouza C, Donovan D, Hershon K, Mazzone T, McGill J, Roberts VL, Umpierrez G, Warren W, Wittlin S, Wyne K. "The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial." *Ann Internal Medicine*. (2010): 346-357. Print.

öke B, Hershon K, Kerr D, Pascual C, Schweizer A, Foley J, Shao Q and Dejager S. Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with metformin. *Horm Metab Res*. 2008 Aug 22.

Clinical Commentaries on Hypertension and CV Risk Management, Kenneth Hershon acknowledged as faculty for this continuing educational activity. Jointly sponsored by the New York Medical College and the Continuing Education Alliance.

Coalition for the Advancement of Cardiovascular Health Risk Watch Newsletter based on Faculty Presentations, Diabetes Consult by Kenneth S. Hershon jointly sponsored by University of Maryland School of Medicine and MEDCON. From a presentation reviewing data on CVD mortality rate in metabolic syndrome is near level of diabetes

Hershon, Kenneth S. "Emerging Options in Type 2 Diabetes." Current Medical Excerpts (2006): 7-8.

Hollander, Priscilla A.; Blonde, Lawrence; Rowe, Richard ; Mehta E. Adi; Milburn, Joseph L.; Hershon S. Kenneth; Chaisson, Jean-Louis; Levin Seymour R. ; entitled "Efficacy and Safety of Inhaled Insulin (Exubera) Compared with Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes." Results of a 6-month, randomized comparative trial. Diabetes Care: Volume 27, Number 10, October 2004.

Hershon, K., Blevins, T., Mayo, C., Roskamp, R.: Original Article entitled "Once-Daily Insulin Glargine Compared with Twice-Daily NPH Insulin in Patients with Type 1 Diabetes" Endocrine Practice: January/February 2004 Volume 10 Number 1 Pages 10-17

Kenneth S. Hershon, Thomas Blevins, Christy May, Ralf Roskamp: Once- Daily Insulin Glargine Compared with Twice-Daily NPH Insulin in Patients with Type-1 Diabetes. Published in Endocrine Practice 2004; 10(no.1)

James LaSalle, Ken Hershon, Lance Berman, Eric Gibson, David Gillen, Jaman Maroni; Utility of amlodipine/atorvastatin single-pill therapy in patients with diabetes mellitus: results from the Gemini study. Abstract European Association in the Study of Diabetes, 2004.

Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab. 2002 Sep;87(9):4171-6. doi: 10.1210/jc.2002-020068. PMID: 12213867.

J. Rosenstock, D. Einhorn, K. Hershon, N.B. Glazer, S. Yu, The Pioglitazone 014 Study Group – Original paper entitled " Efficacy and Safety of Pioglitazone in Type 2 Diabetes: A Randomized, Placebo-Controlled Study in Patients Receiving Stable Insulin Therapy" – International Journal of Clinical Practice: May 2002 Vol. 56, No. 4

Carola, Saloranta, Kenneth Hershon, Michele Ball, Sheila Dickinson and David Holmes: Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia. Published in The Journal of Clinical Endocrinology & Metabolism 87(9): 4171-4176, 2002.

C. Saloranta, D. Holmes, M. Ball, S. Dickinson and K. Hershon – abstract entitled “Efficacy and Safety of Nateglinide in Patients With Mild Hyperglycaemia” – ADA and EASD 2001

Kenneth Hershon, Tom Blevins, David Donley and Christy Littlejohn – abstract entitled “Lower Fasting Blood Glucose (FBG) and Less Symptomatic Hypoglycemia with QD Insulin Glargine (Lantus) Compared to BID NPH in Subjects with Type 1 Diabetes” – 2001 The American Diabetes Association 61st Scientific Sessions

K. Hershon, T. Blevins, D. Donley and C. Littlejohn – abstract entitled “Beneficial Effects of Insulin Glargine Compared to NPH in Subjects with Type 1 Diabetes” – European Association for the Study of Diabetes (EASD) 2001

Kenneth S. Hershon, M.D., Peter Hershon – “Primary, Secondary, Tertiary and Quarternary Treatment With Troglitazone in Type 2 Diabetes Mellitus” Original article: Published in Jan/Feb 2000 issue of Endocrine Practice. vol 6, number 1, p. 20-25

Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999 Oct;20(5):493-510. doi: 10.1016/s0197-2456(99)00024-0. PMID: 10503809.

Harin Padma-Nathan, M.D., Wayne J.G. Hellstrom, M.D., Fran E. Kaiser, M.D., Richard F. Labasky, M.D., Tom F. Lue, M.D., Wolfram E. Nolten, M.D., Paul C. Norwood, M.D., Craig A. Peterson, M.S., Ridwan Shabsigh, M.D., Peter Y. Tam, B.S., Virgil A. Place, M.D., and Neil Gesundheit, M.D., M.P.H., For the Medicated Urethral System For Erection (MUSE) Study Group* - *The members of the MUSE study group are listed in the appendix (Investigators and Coordinators - K.S. Hershon, M.D., Lois Lazerson, M.S., CCRC: Treatment Of Men With Erectile Dysfunction With Transurethral Alprostadil; Published in The New England Journal of Medicine, Vol. 336, No. 1, Jan. 2 1997.

Norwood, P.C., Block, M.B., Bookin, S., Decherney, G.S., Heatley, S.A. Hershon, K.S., Kaiser, F.E. Rosenblatt, S., Rosenstock, J., Gesundheit, N., Spivack, A.P. Stephens, D.E., Tam, P.Y. Place, V.A., and the VIVUS-Muse Study Group, Menlo Park, CA.: Multicenter Double-blind, Placebo-controlled Trial of Transurethral Alprostadil in Diabetic and Nondiabetic Men with Chronic Erectile Dysfunction (Impotence) (Abstract submitted to the American Diabetes's Association's 1996 meeting)

Gentzkow, G., Iwasaki, S., Haynie, K., Hershon, K., Lipkin, S., Steed, D., Mengel, M., Prendergast, J.J., Ricotta, J.: Decreased Recurrence of Diabetic Foot Ulcers After Healing by Cultured Human Dermis. Presented to the Clinical Symposium on Wound Management, Sept 7-9, 1995. Also will be presented at Wound Healing Society in Boston, May 19-24, 1996. (submitted to Symposium on Advance Wound Care)

Shabsigh,S., Barada,J.H., Eid,J.F., Gesundheit,N., Hershon,K.S., Place, V.A., Romas,N.A., Spivack,A.P. and the VIVUS-MUSE Study Group, VIVUS, Inc., Menlo Park, CA.: Treatment Of Erectile Dysfunction (Impotence) With Transurethral Alprostadil: Effects Of Hypertension And AntiHypertensive Medication on Outcome. Accepted by the American Society of Hypertension as a poster presentation on May 17, 1996. Published in the American Journal of Hypertension, Vol. 9, No. 5, Part II.

Gentzkow,G., Iwasaki,S., Haynie,K., Hershon,K.S., Lipkin,S., Steed,D., Mengel,M., Prendergast,J.J., Ricotta,,J.,: Paper on Wound Healing Pilot Study Data for Advanced Tissue Sciences published in Diabetes Care April ed. 1996.

Bo Angelin, Kenneth S. Hershon, and John D. Brunzell entitled “Bile Acid Metabolism in Hereditary Formes of Hypertriglyceridemia: Evidence for an Increased Synthesis Rate in Monogenic Familial Hypertriglyceridemia” PNAS/August 1,1987/vol.84/no.15/5434-5438.

Hershon. K.S., Kelly, W.A., Shaw, C.M., Schwartz, R.B., and Blierman, E.L.,: Prolactinomas as part of the multiple endocrine neoplasia syndrome Type I. American Journal of Medicine, Vol. 74 713-720 April 1983.

Hershon, K.S., Bruzzzone, C., Bierman, E.L., Ensinnck, J.: Effect of naloxone and sodium salicylate on the acute insulin response of Chlorpropamide alcohol flush positive vs. negative non-insulin dependent diabetes (NIDDM). June 1981 (presented at 41st Annual Meeting of American Diabetes Association). Published in Diabetes Care, July-August 1982.

Hershon, K.S., Brunzell, J., Albers, J., Hass, L., Motulsky, A.,: HyperapoB-emia with variable lipid phenotype (Familial Combined Hyperlipidemia). June 1981 (submitted to the American Heart Association 54th Scientific Session).

LECTURES & PRESENTATIONS:

1995-2015 between 15-20 promotional lectures per year for various pharmaceutical companies.

Hershon, K. (Director) (2013, November 16). Life Style Modification Therapy. Diabetes Day for Orimary Car Clinicians. Lecture conducted from AACE, Manhattan.

Hershon, K. (Director) (2011, July 9). Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes . 2011 Diabetes Day for Primary Care Physicians. Lecture conducted from AACE, Manhattan.

June 19, 2010 CME program Insuin Therapy: Minimizing Barriers, Optimizing Treatment Phoenix, AZ

June 12, 2010 CME course "AACE Diabetes Day for Primary Care Physicians" Novel Therapies for Type 2 Diabetes, NY, NY

Feb 9, 2010 CME course, Bisphosphonate therapy for the Management of Osteoporosis, Roslyn NY

October 29, 2009, CME program Incretin Therapy: A New Paradigm in the Treatment of Type 2 Diabetes San Joaquin General Hospital, Fresh Camp, CA

September 29, 2009, CME program Macro- and Microvascular Effects of Hyperglycemia: Addressing Issues and Controversies, Forsyth Medical Center, NC

August 29, 2009 CME course "AACE Diabetes Day for Primary Care Physicians" Novel Therapies for Type 2 Diabetes, NY, NY

April 29, 2009, CME program, Exploring the Dual Defects in Type 2 Diabetes: Insulin Resistance and Beta Cell Dysfunction, Summit NJ

Hershon, Kenneth. "Explore online CME." A Critical Appraisal of the Metabolic Syndrome . 31Oct2006.PriMed.29Apr2008<<http://primed.com/PMO/Activity.aspx?activity=321&StepIndex=1>>.

Hershon, Kenneth. "On Line CME Activity." The Case for Starting Insulin Therapy in Type 2 Diabetes . 22 Jul 2006. PriMed. 29 Apr 2008 <<http://www.primed.com/PMO/Activity.aspx?activity=250>>.

Hershon, Kenneth. "Explore online CME." Is Non-Diabetic Hyperglycemia a CVD Risk Factor? . 17 Feb 2006 . PriMed. 29 Apr 2008 <<http://www.primed.com/PMO/Activity.aspx?activity=139>>.

December 4, 2004 - Grand Rounds- Multispecialty- Blunting the atherosclerotic process: The case for aggressive lipid management. Stormont-Vail Regional Medical Center, Topeka, Kansas

October 23, 2004 – CME course – Multifactorial intervention on macrovascular and microvascular outcomes for diabetes risk reduction: Practical insights and strategies – Atlanta, GA

October 6, 2004 – Grand Rounds – Multiple risk and cardiovascular disease prevention – Jersey City Medical Center, Jersey City, NJ

September 18, 2004 – CME course – Improving outcomes in the metabolic syndrome patient: Targeted approach to CV risk reduction – Seattle, WA

September 18, 2004 – CME course – Improving outcomes in the metabolic syndrome patient: Targeted approach to CV risk reduction – Seattle, WA

September 9, 2004 – CME course – Vascular biology of CV risk: Benefits of multiple risk factor intervention – Washington, DC

July 24, 2004 – CME course – Improving outcomes in the metabolic syndrome patient: Targeted approach to CV risk reduction – Palm Beach, FL

June 26, 2004 – CME course – Interpreting new trial data in multiple risk patients – Orlando, FL

June 11, 2004 – CME course – Concurrent Hypertension And Dyslipidemia: Multiplied Risk for CVD – Norfolk, VA

June 9, 2004 – CME course – From Bench to bedside: Achieving lipid goals in daily practice – Cincinnati, OH

May 22, 2004 – CME course – CV risk reduction in high risk patients: Strategies for prevention – Cleveland, Ohio

May 20, 2004 – CME course – Blunting the atherosclerotic process: The case for aggressive lipid management – Savannah, Georgia

May 1, 2004 – CME course – Cardiorenal protection in the diabetic patient: New Data – New York, New York

April 17, 2004 – CME course – Cardiorenal protection in the diabetic patient: New data – Seattle, Washington

April 1, 2004 – Grand Rounds – Treating Type 2 Diabetes Mellitus – The New Paradigm – Winthrop University Hospital, Mineola, NY

January 14, 2004 – Grand Round – Post-intervention continuum of care: Focus on lipid management in acute and long-term settings. – Bergen Regional Medical Center, Paramus, NJ

November 22, 2003 – CME course – The diabetic: It is sooner than you think – St. Paul, Minnesota

November 15, 2003 – CME course – The diabetic: It is sooner than you think – Chapel Hill, North Carolina

November 8, 2003 – CME course – The diabetic: It is sooner than you think – New Paltz, New York

October 25, 2003 – CME course – The diabetic: It is sooner than you think – Denver, Colorado

October 18, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – Philadelphia, PA

October 4, 2003 – CME course – The diabetic: It is sooner than you think – St. Louis, Missouri

September 18, 2003 – Grand Rounds - Intensive Management of Diabetes – Metropolitan Hospital Center – New York, NY

September 13, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – Chicago, Illinois

September 6, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – New Orleans, Louisiana

August 9, 2003 – CME course – The diabetic – It is sooner than you think – Woodstock, Vermont

August 2, 2003 – CME course – The diabetic – It is sooner than you think – Jackson, Mississippi

July 12, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – San Jose, California

June 28, 2003 – CME course – The diabetic: It is sooner than you think – Hot Springs, Arkansas

June 21, 2003 – CME course – The diabetic: It is sooner than you think – Garden City, New York

June 18, 2003 – Grand Rounds – “Insulin Resistance and CV Disease” – Catholic Medical Center – Manchester, New Hampshire

June 14, 2003 – CME course – The Role of Pharmacotherapy in the Treatment of Dysmetabolic Syndrome – Where Does Diabetes Start? When Should Treatment Start” – New York, New York

May 18, 2003 – CME course – Diabetic Management, an Interactive/Shared Responsibility – Jericho, New York

May 17, 2003 – CME course – The Diabetic: It is sooner than you think – Chicago, Illinois

May 15, 2003 – CME course – The Evolution of Clinical Research in Endocrine Practice – AACE Annual meeting – San Diego, California

May 10, 2003 – CME course - The Diabetic: It is sooner than you think – Fort Lauderdale, Florida

April 12, 2003 – CME course – The Diabetic: It is sooner than you think – Kansas City, Missouri

March 15, 2003 – CME course – Diabetes and CV Disease: Risk equivalents and strategies for treating the total patient – Richmond, Virginia

March 13, 2003 – Grand Rounds – “Redefining Clinical Practice Patterns for Cardiovascular Risk Reduction – New York, New York

February 15, 2003 – CME course – Individualizing Osteoporosis Treatments – Roslyn, New York

January 24, 2003 – CME course – Redefining Clinical Practice Patterns for Cardiovascular Risk Reduction – Torrington, Connecticut

December 5, 2002 – CME course – CV Risk Reduction – Hackensack, New Jersey

December 4, 2002 – CME course – CV Risk Reduction – Great Neck, New York

August 3, 2002 – CME course – The Cardiodynamics of Diabetes Control – Birmingham, Alabama

June 22, 2002 – CME course – The Cardiodynamics of Diabetes Control – Greenville, South Carolina

June 15, 2002 – CME course – The Cardiodynamics of Diabetes Control – Buffalo, NY

May 11, 2002 – CME course – The Cardiodynamics of Diabetes Control – Scottsdale, Arizona

April 22, 2002 – CME course – Fracture Prevention: The Goal for Postmenopausal Osteoporosis Management – Garden city New York

March 23, 2002 – CME courses – The Cardiodynamics of Diabetes Control – St. Paul, Minnesota

February 23, 2002 – CME course – The Cardiodynamics of Diabetes Control – Louisville, Kentucky

January 9, 2002 – CME course – Update on diabetes – Vytra – North Shore – Long Island Jewish Hospital System, NY

December 15, 2001 – CME course – Micro Hope – ACE endothelial dysfunction – Rancho Mirage, CA

December 8, 2001 – CME course – Micro Hope – ACE endothelial dysfunction – Farmington, PA

December 1, 2001 – CME course – Micro Hope – ACE endothelial dysfunction – Kansas City

November 17, 2001 – CME course –Core Curriculum – Micro Hope – ACE endothelial dysfunction, Nappa Valley, CA

September 30, 2001 – CME course – Osteoporosis Update – Nassau, Queens Medical Society, NY

September 19, 2001 – Grand Rounds – Osteoporosis Update – Forest Hills Hospital, Queens, NY

June 30, 2001 – Grand Rounds – Post Prandial Hyperglycemia – Buffalo Hospital, Buffalo, NY

June 27, 2001 – CME course – Insulin in type II diabetes updated – North Shore – Long Island Jewish Hospital System, NY

June 27, 2001 – CME course – Insulin in type II diabetes updated – North Shore – Long Island Jewish Hospital System, NY

June 6, 2001 – CME course – Vascular biology workshop – Micro hope and ACE endothelial dysfunction

April 4, 2001 – CME course – Heterogenesis Etiology of type II DM - It's impact on coronary disease and mortality – North Shore Diabetes & Endocrine Associates – North Shore – Long Island Jewish Hospital System, NY

February 17, 2001 – CME course – New Frontiers in Diabetes Management – Approaches to achieving glycemic control – Presented at Primary Care Medical – West Long Beach California – National meeting

November 28, 2000 – Women’s Wellness Program, North Shore – Long Island Jewish Health System – “Boning Up On Osteoporosis”

July 24, 2000 – Grand Rounds, Downstate Medical Center – “SERMS and Estrogen Receptors”

June 14, 2000 – Grand Rounds, St. Lukes-Roosevelt Hospital Center – “Lipids and Diabetes”

November 10, 1999 – CME Program, Mount Sinai School of Medicine – “New Treatment Options in Type 2 Diabetes”

October 13, 1999 – CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine – “New Management Strategies in Type 2 Diabetes”

October 5, 1999 – Seminar presentation at Montefiore Medical Center – “Treatment, Advances and Update in Diabetes”

Kenneth S. Hershon, M.D., Peter Hershon - abstract entitled “Primary, Secondary, Tertiary and Quarternary Treatment With Troglitazone in Type 2 Diabetes Mellitus” presented at the 1999 Poster Session of the American Association of Clinical Endocrinologists (AACE) Eighth Annual Meeting and Clinical Congress in San Diego, CA April 28 - May 2, 1999.

Julio Rosenstock, M.D., Glen Park, M.D., Joyce Zimmerman, M.D., for the US Study Group of HOE 901 in Type I DM - abstract entitled “Efficacy and Safety of HOE 901 in Patients with Type I DM: A Four-Week Randomized, NPH Insulin-Controlled Trial. - presented in Dallas, TX and Bridgewater, NJ.

Philip Raskin, M.D., Glen Park M.D., Joyce Zimmerman, M.D. for the US Study Group of HOE 901 in Type 2 DM, - abstract entitled “ The Effect of HOE-901 on Glycemic Control in Type 2 Diabetes” - presented in Dallas, TX and Bridgewater, NJ.

April 17, 1999 - Parke-Davis Diabetes Consultants’ Conference - New York, New York “Insulin Resistance: The Primary Defect in Type 2 Diabetes

November 14, 1998 - CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine - “Insulin Resistance Syndrome - Pathway to Glucose Control”

October 10, 1998 - Pfizer/Diabetes Meeting, Seattle, Washington - “Developing New Strategies for Treatment of Type 2 Diabetes”

May 20, 1998 - CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine - "Type 2 Diabetes Training - Incorporating New Treatment Modalities into Clinical Practice"

April 21, 1998 - Science and Medicine Lecture Series, Long Island, NY - "Insulin Resistance: Data and Dialogue"

October 22, 1997 - CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine - "Perspectives on the Treatment and Prevention of Non-Insulin Dependent Diabetes Mellitus"

June 23, 1997 - Annual ADA Meeting, Boston, Mass - Program Chairman for symposium "Late-Breaking Treatment Modalities for Type II Diabetes"

Marshall B. Block, M.D., Stephen Bookin, M.D., G. Stephen DeCherney, M.D., Kenneth S. Hershon, M.D., Wolfram E. Nolten, M.D., Paul C. Norwood, M.D., Sidney Rosenblatt, M.D., Julio Rosenstock, M.D., Julio Rosenstock, M.D., Don S. Schalch, M.D., Sherwyn L. Schwartz, M.D. - abstract entitled "Transurethral Alprostadil for the Treatment of Erectile Dysfunction in Men with Diabetes; Effect of Duration of Diabetes on Efficacy" - presented as a poster presentation at the American Diabetes Association in Boston June 21-24, 1997

Schmer, C., Rastelli, L., Dennis, Jr., M.D., Hershon, K.S., Young, J., Chait, A.,: Removal of low density lipoprotein in sheep by extracorporeal affinity chromatography. June 1981 sheep by extracorporeal affinity chromatography. June 1981 (presented at the meeting of the American Society for Artificial Internal Organs).

Fujimoto, W.J., Hershon, K.S., Kinyoun, J.L., Okamoto, J., Ring, E., Stolov, W.C., Gale, J.C.: Maturity onset diabetes in second generation Japanese Americans (Nisei) and Caucasian males in Seattle Washington: A pilot study. February 1981 (presented at the meeting of the Third Symposium on Diabetes Mellitus in Asia and Oceania).

Stolov, W.C., Fujimoto, W.Y., Hershon, K.S., and Thompson, S.C.: Neuropathy and biochemical abnormalities in Japanese and Caucasian subjects with non-insulin dependent maturity onset diabetes. September 1980 (presented at the meeting of the American Association of Electromyography and electrodiagnosis).

Rayfield, E.J., Hershon, K.S., Morgan, G., and Freeman, J.R.: Islet Cell Surface Antibodies in Pancreatic Disease. June 1979 (presented at 39th annual meeting of American Diabetes Association).

RESEARCH:

Principal Investigator	Injectable treatment for hyperlipidemia, Vesalius	Amgen
Principal Investigator	Biosimilar short acting insulin	Mylan
Principal Investigator	Injectable treatment for hyperlipidemia	Regeneron
Principal Investigator	Treatment for elevated triglycerides	Kowa
Principal Investigator	Injectable treatment for hyperlipidemia	Regeneron
Principal Investigator	Oral Diabetic	GlaxoSmithKline
Principal Investigator	Oral Diabetic	GlaxoSmithKline
Principal Investigator	Injectable treatment for hyperlipidemia	Amgen
Principal Investigator	Oral diabetic agent added to insulin in type 1 diabetic	Bristol-Myers Squibb
Principal Investigator	Oral Diabetic Agent/renal disease	Janssen Research and Development
Principal Investigator	Glucose measuring device	Novanex
Principal Investigator	AMG 145 on Cognitive function	Amgen
Principal Investigator	MACE assessment of a weight loss medication	Eisai
Principal Investigator	Diabetic Nephropathy	AbbVie
Principal Investigator	Infusible medication for insulin pump	Halozyne Therapeutics
Principal Investigator	MACE assessment of an Oral Diabetic Agent	AstraZeneca
Principal Investigator	Insulin for Type 2 Diabetics	Sanofi
Principal Investigator	Insulin	Sanofi Aventis
Principal Investigator	Insulin	Sanofi Aventis
Principal Investigator	Injectable treatment for hyperlipidemia	Amgen
Principal Investigator	Oral diabetic agent	Bristol-Myers Squibb
Principal Investigator	Oral Diabetic Agent	Bristol-Myers Squibb
Principal Investigator	Mace assessment of weight loss medication	Orexigen
Principal Investigator	Diabetic Nephropathy	Abbvie
Principal Investigator	Inhaled insulin Type 2	MannKind
Principal Investigator	Inhaled insulin Type 1	MannKind
Principal Investigator	Oral Diabetic Agent	Boehringer Ingelheim

Principal Investigator	Oral Diabetic	AstraZeneca
Principal Investigator	Oral diabetic medication in Type 1 subjects	BMS/AZ
Principal Investigator	Insulin for Type 1 Diabetics	Lilly
Principal Investigator	Insulin for Type 2 Diabetics	Lilly
Principal Investigator	Inhaled insulin Type 2	MannKind
Principal Investigator	MACE assessment of an oral diabetic Medication	AstraZeneca
Principal Investigator	Oral Diabetic Agent	Boehringer Ingelheim
Principal Investigator	Inhaled insulin	MannKind
Principal Investigator	Inhaled insulin type 1	MannKind
Principal Investigator	Inhaled insulin type 2	MannKind
Principal Investigator	Inhaled insulin (COPD)	MannKind
Principal Investigator	Diabetic Nephropathy	Fibrogen
Principal Investigator	Hypertension	Forest Research
Principal Investigator	Obesity medication for type 2 diabetic patients	Intarcia Therapeutics
Principal Investigator	Insulin Delivery Device	Valeritas
Principal Investigator	Oral Diabetic Agent	Akros
Principal Investigator	Oral Diabetic Agent	Forest Research
Principal Investigator	Oral Diabetic Agent	Forest Research
Principal Investigator	Oral Diabetic Agent	Johnson & Johnson
Principal Investigator	Insulin/ Type 2 Diabetics	NovoNordisk
Principal Investigator	Hypertension	Novartis
Principal Investigator	Oral Diabetic Agent	National Institute of Health
Principal Investigator	Oral Diabetic Agent	National Institute of Health
Principal Investigator	Nephropathy	Nephrogenex
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Injectable diabetic medication	Amylin
Principal Investigator	Oral Diabetic Agent	Johnson & Johnson
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	Neuropathy	Abbott
Principal Investigator	Hypertension	Takeda
Principal Investigator	Injectable diabetic medication	Amylin

Principal Investigator	Inhaled insulin (device)	MannKind
Principal Investigator	Lipid/Diabetes	Merck
Principal Investigator	Inhaled insulin Type 1	MannKind
Principal Investigator	Oral Diabetic Agent in elderly	Merck
Principal Investigator	Inhaled insulin Type 2	MannKind
Principal Investigator	Inhaled insulin Type 1	MannKind
Principal Investigator	Injectable Diabetic Medication	Sanofi Aventis
Principal Investigator	inhaled insulin	NovoNordisk
Principal Investigator	Lipid	Merck
Principal Investigator	Fast Acting Insulin + Extension	Novo Nordisk
Principal Investigator	Hypertension	Novartis
Principal Investigator	Hypertension	NovoNordisk
Principal Investigator	Lipid	Merck
Principal Investigator	inflammation in subjects with metabolic syndrome	Bristol-Myers
Principal Investigator	Oral Diabetic (Extension)	Takeda
Principal Investigator	Inhaled Insulin	Eli Lilly
Principal Investigator	Renal Insufficiency	Keryx
Principal Investigator	Renal Insufficiency	Keryx
Principal Investigator	insulin	Novo Nordisk
Principal Investigator	Renal Insufficiency	Speedel
Principal Investigator	Insulin type 2	Sanofi aventis
Principal Investigator	LADA	DeveloGen Israel Ltd.
Principal Investigator	Lipid	Merck
Principal Investigator	Lipid	Merck
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Oral Diabetic Agent in treatment naïve subjects	BristolMyers
Principal Investigator	Oral Diabetic	AstraZeneca
Principal Investigator	Inhaled Insulin	Pfizer
Principal Investigator	Inhaled Insulin	Pfizer
Principal Investigator	Hypertension	Novartis
Principal Investigator	Testosterone replacement	Auxilium
Principal Investigator	Insulin	Sanofi Aventis
Principal Investigator	Diabetic Oral Agent	Takeda America
Principal Investigator	Lipids	Pfizer
Principal Investigator	Oral Diabetic	Novartis

Principal Investigator	Inhaled Insulin	Pfizer
Principal Investigator	Oral Diabetic	GlaxoSmithKline
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	Oral Diabetic	Metabolex
Principal Investigator	Hypertension	Novartis
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	Hyperlipidemia	Merck
Principal Investigator	Oral Diabetic	Bristol-Myers
Principal Investigator	Oral Diabetic	Bristol-Myers Squibb
Principal Investigator	Type 2 oral med vs. insulin	Aventis
Principal Investigator	Oral Diabetic	AstraZeneca
Principal Investigator	Oral Diabetic agent	Bristol-Myers Squibb
Principal Investigator	Diabetic Hypertension	Pfizer
Principal Investigator	Insulin + Oral Diabetic	GlaxoSmithKline
Principal Investigator	Inhaled insulin Type 1	Eli Lilly
Principal Investigator	Inhaled insulin Type 2	Eli Lilly
Principal Investigator	Cardiovascular	AstraZeneca
Principal Investigator	Oral Diabetic (OLE)	Takeda
Principal Investigator	Hypopituitary	Eli Lilly
Principal Investigator	Hypertension/Hyperlipidemia	Pfizer
Principal Investigator	type 2 oral med vs insulin	Aventis
Principal Investigator	standard vs aggressive insulin dose adjustments on a1c	Aventis
Principal Investigator	Inhaled Insulin - Type 1 & 2	Pfizer
Principal Investigator	Hemoglobin-Renal Insufficiency	OrthoBiotech
Principal Investigator	Hyperlipidemia	Bristol-Myers Squibb
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	Lipids/Diabetes	Merck
Principal Investigator	insulin type 2	Aventis
Principal Investigator	Cardiovascular outcomes IGT	Novartis
Principal Investigator	Osteoporosis	Wyeth-Ayerst
Principal Investigator	Pump	Restoragen

Principal Investigator	Pump	Restoragen
Co Principal Investigator	Neuropathy (DNA)	Pfizer
Principal Investigator	Diabetic Oral Agent	Bristol-Myers Squibb
Principal Investigator	insulin type 1	Aventis
Principal Investigator	insulin type 2	Novo Nordisk
Principal Investigator	Lipid/Diabetes	Merck
Sub-Investigator	Diabetic Foot Ulcers	Advanced Tissue Sciences
Principal Investigator	Non-Healing Foot Ulcer Study Phase II	Advanced Tissue Sciences
Principal Investigator	Non-healing Foot Ulcer Study Phase III	Advanced Tissue Sciences
Principal Investigator	Diabetic Oral Agent	Bristol-Myers Squibb
Principal Investigator	Fast Acting Insulin Combination	Eli Lilly
Principal Investigator	Oral Diabetic	Wyeth-Ayerst
Principal Investigator	Retinopathy progression in type 2 DM patients treated with insulin	Aventis
Principal Investigator	Oral Diabetic	Insmed
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Oral Diabetic	Bristol-Myers
Principal Investigator	Oral Diabetic	Bristol-Myers
Principal Investigator	Oral Diabetic	Aventis
Principal Investigator	Oral Diabetic	Pfizer
Principal Investigator	Insulin type 2	Aventis
Principal Investigator	Oral Diabetic	Pfizer
Principal Investigator	Oral Diabetic	Pfizer
Principal Investigator	Diabetic Oral Agent	Takeda America
Investigator	Oral Diabetic	Pharmacia & Upjohn
Principal Investigator	Oral Diabetic	AstraZeneca
Principal Investigator	Hypertension	Bristol-Myers Squibb
Principal Investigator	Lipid/Diabetes	Merck
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	URI	ViroPharma
Principal Investigator	Anemia in Early Renal Insufficiency	OrthoBiotech

Principal Investigator	Oral Diabetic agent	Merck
Principal Investigator	Oral Diabetic	Bristol-Myers
Principal Investigator	Anemia in Early Renal Insufficiency	OrthoBiotech
Principal Investigator	Oral Diabetic	Parke-Davis
Principal Investigator	Painful Diabetic Neuropathy	Bristol-Myers Squibb
Principal Investigator	New Insulin - Type I	Hoechst Marion Roussel
Principal Investigator	Oral Diabetic	Glaxo Wellcome
Principal Investigator	Oral Diabetic	Glaxo Wellcome
Principal Investigator	Oral Diabetic	Parke-Davis
Principal Investigator	Oral Diabetic	Takeda America
Principal Investigator	Efficacy and safety of hypertensive agent	Bristol-Myers Squibb
Principal Investigator	Oral Diabetic	Glaxo Wellcome
Principal Investigator	Lipid Lowering	Parke-Davis/Pfizer
Principal Investigator	Hypercholesterolemia in Postmenopausal	Parke-Davis/Pfizer
Principal Investigator	Oral Diabetic 2 OF 3	Glaxo Wellcome
Sub-Investigator	Diabetic Foot Ulcer	Ortec
Sub-Investigator	Treatment Resistant Depression	Eli Lilly
Principal Investigator	Hypertriglyceridemia	Rhone-Poulenc Rorer
Principal Investigator	Infected Diabetic Foot Ulcers	Pfizer
Principal Investigator	Human growth factor in subjects with diabetic neuropathy	Genentech
Principal Investigator	Hyperlipidemia Type 2	SmithKline Beecham
Principal Investigator	Oral Diabetic	Parke-Davis
Principal Investigator	Inhaled Insulin type 1	Pfizer
Principal Investigator	Inhaled Insulin type 2	Pfizer
Principal Investigator	Inhaled Insulin type 2	Pfizer
Principal Investigator	Inhaled Insulin	Pfizer
Principal Investigator	Oral Diabetic agent	Bristol-Myers Squibb
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Obesity & Diabetes	Amgen
Principal Investigator	Painful peripheral neuropathy	NovoNordisk
Co Principal Investigator	Neuropathy	Parke-Davis

Principal Investigator	Obesity	Roche
Principal Investigator	HRT	Berlex Labs
Co-Investigator	Diabetic Macular Edema	Eli Lilly
Co-Investigator	Diabetic Retinopathy	Eli Lilly
Principal Investigator	Diabetic Foot Ulcers	Mylan
Principal Investigator	Oral Diabetic	Roche Laboratories Inc
Principal Investigator	Isolated systolic hypertension	Bristol-Myers Squibb
Principal Investigator	Oral Diabetic	Parke-Davis
Principal Investigator	Diabetic Polyneuropathy	Pfizer
Principal Investigator	Hypertension and microalbuminuria or overt nephropathy	Bristol-Myers Squibb
Principal Investigator	Oral Diabetic	Bristol-Myers Squibb
Principal Investigator	Obesity	Wyeth-Ayerst
Principal Investigator	Diabetic Oral Agent	Takeda America
Principal Investigator	Mild to Moderate Hypertension in elderly	Bristol-Myers Squibb
Principal Investigator	Disposable Pen	Eli Lilly
Principal Investigator	Obesity & Diabetes	Amgen
Principal Investigator	Oral Diabetic	Novartis
Principal Investigator	Hypertension	Novartis
Principal Investigator	Hyperlipidemia Type 2	SmithKline Beecham
Principal Investigator	Oral Diabetic	Parke-Davis
Co-Investigator	Diabetic Foot Ulcer	Organogenesis
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	Diabetic Oral Agent	GlaxoWellcome
Principal Investigator	New Insulin - Type I	Hoechst Marion Roussel
Principal Investigator	Oral Diabetic	Bristol-Myers Squibb
Principal Investigator	Endometrial Hyperplasia	Eli Lilly
Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	New Insulin - Type II	Hoechst Marion Roussel
Principal Investigator	Diabetic Nephropathy, Type II	Alteon
Principal Investigator	Diabetic Oral Agent	SmithKline Beecham Pharmaceuticals

Principal Investigator	Oral Diabetic	Takeda
Principal Investigator	Diabetic Oral Agent	Takeda
Principal Investigator	Diabetic Oral Agent	Takeda America
Principal Investigator	Diabetes treatment	Genentech
Principal Investigator	Diabetic Oral Agent	SmithKline Beecham Pharmaceuticals
Principal Investigator	Hormone Patch	Ethical Pharmaceuticals
Principal Investigator	Diabetic Oral Agent	SmithKline Beecham Pharmaceuticals
Principal Investigator	Diabetic Oral Agent	Takeda America
Principal Investigator	Diabetic Oral Agent	Takeda America
Principal Investigator	Diabetic Oral Agent	SmithKline Beecham Pharmaceuticals
Principal Investigator	Hormone Patch	Wyeth-Ayerst
Sub-Investigator	ACS Vitreous Hemorrhage Clearing Study	Advanced Corneal Systems
Principal Investigator	Obesity	Wyeth-Ayerst
Principal Investigator	Obesity	Wyeth-Ayerst
Principal Investigator	Insulin for Type 2 Diabetics	Lilly
Principal Investigator	Erectile Dysfunction	Schiff & Co.
	Fast Acting Insulin	Novo Nordisk
Co-Investigator	Diabetic Oral Agent	Upjohn
Principal Investigator	Hypopituitary	Eli Lilly
Sub-Investigator	Breast cancer	Boehringer- Mannheim
Principal Investigator	Achieve - Accupril in CHF	Parke-Davis
Principal Investigator	Diabetic Oral Agent	Bayer
Principal Investigator	Diabetic Oral Agent	Parke-Davis
Principal Investigator	Erectile dysfunction Phase II	Vivus
Principal Investigator	Erectile dysfunction Phase III & Open-label	Vivus
Principal Investigator	Diabetic Nephropathy Type I	Alteon
Co-Investigator	Alzheimer	Pfizer
Principal Investigator	Post menopausal women	Eli Lilly
Principal Investigator	Osteoporosis	Eli Lilly
Principal Investigator	Peripheral Arterial Occlusive Disease	Alpha Therapeutic Corporation

Co-Investigator	Diabetic Foot ulcer	Apo Pharma
Principal Investigator	Insulin in elderly type 2 diabetes	Boehringer Ingelheim
Principal Investigator	Insulin + oral agent	Brigham and Women's Health Hospital
Principal Investigator	Diabetic Gastroparesis	Janssen Research Foundation
Principal Investigator	Infected Diabetic Foot Ulcers	Magainin
Principal Investigator	Proteinuria	Merck
Principal Investigator	Osteoporosis	Merck
Principal Investigator	Diabetic Lower Extremity Ulcers	Oxford
Principal Investigator	Oral Diabetic	Pharmacia & Upjohn
Principal Investigator	Diabetic Oral Agent & CHF	SmithKline Beecham Pharmaceuticals
Principal Investigator	Renal Impairment Type II Diabetics	Takeda
Principal Investigator	Foot Ulcer Study	Telios
Principal Investigator	Essential Hypertension	Wyeth-Ayerst
Principal Investigator	Management of Diabetic Foot Ulcers	Zymogenetics Inc.
Co-Investigator	Diabetic oral agent	Roerig-Pratt